N-adamantan-2-yl-2-{1-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-cyclopentyl}-acetamide | 1034144-15-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-adamantan-2-yl-2-{1-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-cyclopentyl}-acetamide
• 英文别名: N-(2-adamantyl)-2-[1-[[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]methyl]cyclopentyl]acetamide
• CAS: 1034144-15-4
• 化学式: C₂₇H₃₅N₃O₃
• 分子量: 449.593
• InChiKey: IHFDAYOHEILBLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  77.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
  申请人：Merck Sante

  公开号：EP1935420A1

  公开（公告）日：2008-06-25

  The present invention relates to 2-adamantyl-butyramide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11 β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.

  本发明涉及公式I的2-金刚烷基丁酰胺衍生物，作为选择性抑制酶11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的抑制剂，以及这种化合物用于治疗和预防代谢综合征、糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、青光眼、骨质疏松症、认知障碍、焦虑、抑郁、免疫障碍、高血压和其他疾病和病症的用途。
• 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS
  申请人：Merck Patent GmbH

  公开号：EP2094263A1

  公开（公告）日：2009-09-02
• 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES
  申请人：Merck Sharp & Dohme B.V.

  公开号：EP2318368B1

  公开（公告）日：2013-10-16
• 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS
  申请人：Roche Didier

  公开号：US20100022597A1

  公开（公告）日：2010-01-28

  The present invention relates to 2-adamantyl-butyramide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
• DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS
  申请人：MacCoss Malcolm

  公开号：US20110286969A1

  公开（公告）日：2011-11-24

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as wet! as methods of using them to treat disorders associated with the HCV protease An illustrative inventsve compound is shown below: Formula (I).